Nice approves Relugolix, first oral hormone reduction pill for 40,000 English prostate cancer patients.
A groundbreaking hormone reduction pill, Relugolix (Orgovyx), has been approved by the National Institute for Health and Care Excellence (Nice) for 40,000 men in England with advanced prostate cancer. The oral medication, the first of its kind, inhibits testosterone production in the testicles and offers a convenient and flexible treatment option compared to injectable therapies. Relugolix is expected to be available to NHS patients within three months.
July 19, 2024
5 Articles